1-naphthylamine has been researched along with Cirrhosis, Liver in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| He, HW; Hu, SJ; Lu, ZN; Shan, Q; Wang, JX; Yu, DK; Zhang, GN; Zhao, Y; Zhu, M | 1 |
| Angebaud, P; Coates, P; Démolis, JL; Funck-Brentano, C; Grangé, JD; Jaillon, P | 1 |
2 other study(ies) available for 1-naphthylamine and Cirrhosis, Liver
| Article | Year |
|---|---|
Discovery of 1,8-naphthalidine derivatives as potent anti-hepatic fibrosis agents via repressing PI3K/AKT/Smad and JAK2/STAT3 pathways.
Topics: 1-Naphthylamine; Cell Proliferation; Cells, Cultured; Dose-Response Relationship, Drug; Drug Discovery; Humans; Janus Kinase 2; Liver Cirrhosis; Molecular Structure; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Smad Proteins; STAT3 Transcription Factor; Structure-Activity Relationship | 2021 |
Influence of liver cirrhosis on sertraline pharmacokinetics.
Topics: 1-Naphthylamine; Adult; Aged; Antidepressive Agents; Female; Humans; Liver Cirrhosis; Male; Middle Aged; Selective Serotonin Reuptake Inhibitors; Sertraline | 1996 |